I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 29, 2018 | Series C | $220M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
— | Series C |
|
— | Series C |